CARA Cara Therapeutics Inc

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update.

To participate in the conference call, please register . Registrants will receive the dial-in numbers and a unique PIN.

A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the Investors section of the Company’s website at .

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin, with an ongoing Phase 2/3 clinical program for patients with notalgia paresthetica, a neuropathic disorder characterized by chronic pruritus of the upper back for which there are no FDA-approved therapies. For more information, visit and follow the company on , and .

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

INVESTOR CONTACT:

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700

 



EN
12/02/2024

Underlying

CARACara Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cara Therapeutics Inc

 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics to Announce First Quarter 2024 Financial Results on ...

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under “Press Releases” in the Investors section of the Company’s website at . About Cara Therapeutics Cara Therapeu...

8h / 7m 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Health...

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT. A webcast of the presentation can be accessed under "Events & Presentations" in the ...

April 2, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event...

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader (KOL) event titled “Meet the NP Experts” on Wednesday, March 27, 2024, at 10:00 a.m. EDT. The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemio...

March 7, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financia...

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA),...

March 4, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financ...

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register . Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be availab...

February 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch